Clinical behavior of non-muscle-invasive bladder cancer (NMIBC) is largely unpredictable, and even patients treated according to European Association of Urology recommendations have a heterogeneous prognosis. High-grade T1 (HGT1) bladder cancer is the highest-risk subtype of NMIBC, with an almost 40% rate of recurrence and 20% of progression at 5 years. Nomograms predicting risk of recurrence, progression, and cancer-specific survival (CSS) are not available specifically within HGT1 bladder cancer, and the identification of robust prognostic biomarkers to better guide therapeutic strategies in this subgroup of patients is of paramount importance. Strategies to identify putative biomarkers in liquid biopsies from blood and urine collected from patients with bladder cancer have been intensively studied in the last few years.

Circulating tumor cells identify patients with super-high-risk non-muscle-invasive bladder cancer: updated outcome analysis of a prospective single-center trial / Nicolazzo, Chiara; Busetto, Gian Maria; Gradilone, Angela; Sperduti, Isabella; Del Giudice, Francesco; Loreni, Flavia; Cortesi, Enrico; de Berardinis, Ettore; Gazzaniga, Paola; Raimondi, Cristina. - In: THE ONCOLOGIST. - ISSN 1083-7159. - 24:5(2019), pp. 612-616. [10.1634/theoncologist.2018-0784]

Circulating tumor cells identify patients with super-high-risk non-muscle-invasive bladder cancer: updated outcome analysis of a prospective single-center trial

Nicolazzo, Chiara
Primo
;
Busetto, Gian Maria
Secondo
;
Gradilone, Angela;Del Giudice, Francesco;Loreni, Flavia;Cortesi, Enrico;de Berardinis, Ettore;Gazzaniga, Paola
Penultimo
;
Raimondi, Cristina
Ultimo
2019

Abstract

Clinical behavior of non-muscle-invasive bladder cancer (NMIBC) is largely unpredictable, and even patients treated according to European Association of Urology recommendations have a heterogeneous prognosis. High-grade T1 (HGT1) bladder cancer is the highest-risk subtype of NMIBC, with an almost 40% rate of recurrence and 20% of progression at 5 years. Nomograms predicting risk of recurrence, progression, and cancer-specific survival (CSS) are not available specifically within HGT1 bladder cancer, and the identification of robust prognostic biomarkers to better guide therapeutic strategies in this subgroup of patients is of paramount importance. Strategies to identify putative biomarkers in liquid biopsies from blood and urine collected from patients with bladder cancer have been intensively studied in the last few years.
File allegati a questo prodotto
File Dimensione Formato  
Nicolazzo_Circulating Tumor Cells_2019.pdf

accesso aperto

Note: https://theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2018-0784
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 338.09 kB
Formato Adobe PDF
338.09 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1259469
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 31
social impact